Breakthrough gene therapy jab reverses hearing loss in weeks
A single jab consisting of a breakthrough gene therapy can be reversed hearing loss According to new research, people in weeks.
The last therapy heard in children and adults Congenital deafness Or a 7 -year -old 7 -year -old hearing impairment in a 7 -year -old clinical research, researchers SwedishKarolinska said Institutet.
. clinical trialdetailed in the magazine Nature MedicalA healthy copy Again It was injected into it ear Improved hearing of all 10 of the participants.
Small -scale trial contained people with a genetic deafness or serious hearing impairment. Mutations in a Gende named Otof.
These mutations cause protein autoferlin deficiency, which plays an important role in transferring sound signals from the ear to the brain.
Although therapy seems to be the best in children, researchers said that they could benefit adults.
Representation. A breakthrough can revers the hearing loss of gene therapy within a single jab weeks (AFP via Getty)
In the experiment, a synthetic, harmless version of the virus associated with Adeno was used to give a proper functional gene to the inner ear through a single injection.
The effects of treatment were prominent in most patients who recovered rapidly only one month later.
Six months later, the researchers rose to a significant hearing improvement in all participants, the average perceived sound volume rose from 106 to 52 to 52.
In this study, people between the ages of five and eight found the best response to treatment.
A seven -year -old girl quickly saved almost all her hearings, and four months later she was able to have daily talks with her mother.
Maoli Duan, the author of Karolinska Institutet’s work, said, “This is the first time in young people and adults.
“In most of the participants, the hearing has greatly recovered, which may have a deep impact on the quality of life. Now we will follow these patients to see how permanent the effect is.”
The researchers also found that treatment was safe and well tolerated. Participants did not report serious negative reactions in the 6-12-month follow-up period.
The most common reaction is a decrease in the number of neutrophils of the immune system, a kind of white blood cell.
Oto Otof is just starting, Dr Dr Duan said, researchers are working on other common genes behind the deafness, such as GJB2 and TMC1.
“These are more complex, but animal studies have returned to promising results. We are sure that patients with different types of genetic deafness can receive treatment for one day.”
